NAMS
NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Co N.V. insider trading
Insiders at NewAmsterdam Pharma Co N.V. have been buying its stock on the open market. The largest purchase in the last 30 days was Davidson Michael H. (Chief Executive Officer · Director) buying $226.5K of NAMS, filed Sep 15, 2026. Every open-market purchase and sale its officers, directors and 10% owners filed in that time is listed below, each linked to the original Form 4.
- Bought on the open market
- $226.5K
- Sold
- —
- Insiders
- 1
- Latest trade
- Sep 14, 2026
From SEC filings · last 30 days
Recent NAMS insider transactions
Davidson Michael H.Chief Executive Officer · Director
Bought 10,000 sh at $22.65 · Sep 14, 2026
$226.5K
Filing
SEC Form 4 data, Q3 2024 to Q2 2026
NAMS insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 12 insiders traded NAMS on the open market: 10 purchases worth $503.7K and 75 sales worth $100.2M, 60 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 3 purchases ($58.4K) and 46 sales ($64.5M), by 7 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | −$3.5M3 sales · all on a plan | |
| Q1 2026 | — | −$46.7M30 sales · 24 on a plan | |
| Q4 2025 | — | −$5.2M3 sales · all on a plan | |
| Q3 2025 | +$58.4K3 buys | −$9.1M10 sales · 3 on a plan | |
| Q2 2025 | +$236.8K3 buys | −$1.9M2 sales · all on a plan | |
| Q1 2025 | +$109.7K2 buys | −$3.1M1 sale | |
| Q4 2024 | — | −$30.7M26 sales · 25 on a plan | |
| Q3 2024 | +$98.7K2 buys | — |
- Largest purchase
- +$167.4K of NAMS by Topper James N (Director) on Jun 16, 2025.
- Largest sale
- −$14.8M of NAMS by Davidson Michael H. (Chief Executive Officer · Director) on Mar 02, 2026.
Open-market transactions through Jun 30, 2026most recent first
Kooij Louise Frederika10b5-1
Chief Accounting Officer
−$1.2M
Jun 22, 2026
39,700 sh · $30.20
Kooij Louise Frederika10b5-1
Chief Accounting Officer
−$9.2K
Jun 22, 2026
300 sh · $30.73
Kooij Louise Frederika10b5-1
Chief Accounting Officer
−$2.3M
May 26, 2026
65,000 sh · $35.69
Lange Louis G
Director
−$1.3M
Mar 11, 2026
44,173 sh · $30.41
Lange Louis G
Director
−$13.9K
Mar 11, 2026
446 sh · $31.23
Kastelein Johannes Jacob Pieter10b5-1
Chief Scientific Officer · Director
−$3.1M
Mar 09, 2026
101,409 sh · $30.29
Kastelein Johannes Jacob Pieter10b5-1
Chief Scientific Officer · Director
−$2.9M
Mar 06, 2026
94,124 sh · $30.32
Lange Louis G
Director
−$829K
Mar 06, 2026
28,186 sh · $29.41
Kastelein Johannes Jacob Pieter10b5-1
Chief Scientific Officer · Director
−$3.2M
Mar 05, 2026
104,467 sh · $30.30
Davidson Michael H.
Chief Executive Officer · Director
−$14.8M
Mar 02, 2026
443,707 sh · $33.25
Davidson Michael H.10b5-1
Chief Executive Officer · Director
−$5.6M
Feb 26, 2026
165,408 sh · $33.63
Davidson Michael H.10b5-1
Chief Executive Officer · Director
−$617.3K
Feb 26, 2026
17,924 sh · $34.44
Davidson Michael H.10b5-1
Chief Executive Officer · Director
−$1.6M
Feb 25, 2026
46,517 sh · $35.11
Davidson Michael H.10b5-1
Chief Executive Officer · Director
−$375.3K
Feb 25, 2026
10,436 sh · $35.96
Davidson Michael H.10b5-1
Chief Executive Officer · Director
−$47.7K
Feb 25, 2026
1,300 sh · $36.68
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Jun 22, 2026 | Kooij Louise Frederika10b5-1Chief Accounting Officer | 39,700 | $30.20 | −$1.2M |
| Jun 22, 2026 | Kooij Louise Frederika10b5-1Chief Accounting Officer | 300 | $30.73 | −$9.2K |
| May 26, 2026 | Kooij Louise Frederika10b5-1Chief Accounting Officer | 65,000 | $35.69 | −$2.3M |
| Mar 11, 2026 | Lange Louis GDirector | 44,173 | $30.41 | −$1.3M |
| Mar 11, 2026 | Lange Louis GDirector | 446 | $31.23 | −$13.9K |
| Mar 09, 2026 | Kastelein Johannes Jacob Pieter10b5-1Chief Scientific Officer · Director | 101,409 | $30.29 | −$3.1M |
| Mar 06, 2026 | Kastelein Johannes Jacob Pieter10b5-1Chief Scientific Officer · Director | 94,124 | $30.32 | −$2.9M |
| Mar 06, 2026 | Lange Louis GDirector | 28,186 | $29.41 | −$829K |
| Mar 05, 2026 | Kastelein Johannes Jacob Pieter10b5-1Chief Scientific Officer · Director | 104,467 | $30.30 | −$3.2M |
| Mar 02, 2026 | Davidson Michael H.Chief Executive Officer · Director | 443,707 | $33.25 | −$14.8M |
| Feb 26, 2026 | Davidson Michael H.10b5-1Chief Executive Officer · Director | 165,408 | $33.63 | −$5.6M |
| Feb 26, 2026 | Davidson Michael H.10b5-1Chief Executive Officer · Director | 17,924 | $34.44 | −$617.3K |
| Feb 25, 2026 | Davidson Michael H.10b5-1Chief Executive Officer · Director | 46,517 | $35.11 | −$1.6M |
| Feb 25, 2026 | Davidson Michael H.10b5-1Chief Executive Officer · Director | 10,436 | $35.96 | −$375.3K |
| Feb 25, 2026 | Davidson Michael H.10b5-1Chief Executive Officer · Director | 1,300 | $36.68 | −$47.7K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Don't check NAMS — let it ping you
Watch every insider filing the minute it clears the SEC
The live dashboard reads every Form 4 as it lands and puts it in plain English — open-market buys, cluster buys where several insiders move at once, and the sales executives chose to make rather than scheduled. Free to open; Pro adds alerts, watchlists and each buyer's track record.
NewAmsterdam Pharma Co N.V. is outside the 777 companies InsiderPulse scans continuously. This page is built from the filings on the live tape and stays up while its insiders are buying. Monitoring, not advice.
Other companies insiders are buying now
Questions
- Are NAMS insiders buying or selling?
- Between Sep 14, 2026 and Sep 14, 2026, 1 NewAmsterdam Pharma Co N.V. insider made 1 open-market purchase worth $226.5K and no sales, a net purchase of $226.5K.
- How much NAMS stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 12 NewAmsterdam Pharma Co N.V. insiders made 10 open-market purchases worth $503.7K and 75 sales worth $100.2M. 60 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: 3 purchases ($58.4K) and 46 sales ($64.5M). The largest purchase was Topper James N buying $167.4K on Jun 16, 2025. The largest sale was Davidson Michael H. selling $14.8M on Mar 02, 2026.
- What was the largest recent NAMS insider trade?
- Davidson Michael H. (Chief Executive Officer · Director) bought $226.5K of NAMS stock on Sep 14, 2026 at about $22.65 a share.
- When did an insider last buy NAMS shares?
- The most recent open-market purchase on file is Davidson Michael H. (Chief Executive Officer · Director) buying $226.5K on Sep 14, 2026.
- Where does NAMS insider trading data come from?
- From the Form 4 filings NewAmsterdam Pharma Co N.V.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.